Afya (NASDAQ:AFYA) VP Sells $215,740.00 in Stock

April 15, 2026 by InsiderTrades.com

Key Points

Afya VP De Sousa Anibal Jose Grifo sold 14,000 shares on April 13 at an average price of $15.41 for $215,740, leaving him with 31,000 shares — a 31.11% reduction in his ownership; he also sold 5,000 shares on April 7.
The company reported Q results that beat EPS estimates ($0.41 vs. $0.36) but missed revenue expectations ($147.08M vs. $174.74M); Afya has a market cap of $1.45B and a P/E of 10.59.
Afya recently paid an annual dividend of $0.656 (the article states a dividend yield of 433%), and analysts’ consensus is a "Hold" with an average price target of $17.30.

Afya Limited (NASDAQ:AFYA - Get Free Report) VP De Sousa Anibal Jose Grifo sold 14,000 shares of the business's stock in a transaction dated Monday, April 13th. The stock was sold at an average price of $15.41, for a total value of $215,740.00. Following the transaction, the vice president owned 31,000 shares of the company's stock, valued at $477,710. The trade was a 31.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

De Sousa Anibal Jose Grifo also recently made the following trade(s):

On Tuesday, April 7th, De Sousa Anibal Jose Grifo sold 5,000 shares of Afya stock. The stock was sold at an average price of $15.20, for a total value of $76,000.00.

Afya Price Performance

Afya stock opened at $15.46 on Wednesday. The firm has a market capitalization of $1.45 billion, a P/E ratio of 10.59, a PEG ratio of 0.70 and a beta of 0.48. Afya Limited has a 1 year low of $13.00 and a 1 year high of $19.90. The business has a 50-day moving average of $14.50 and a 200-day moving average of $14.67. The company has a current ratio of 2.20, a quick ratio of 2.20 and a debt-to-equity ratio of 0.41.

Afya (NASDAQ:AFYA - Get Free Report) last posted its earnings results on Wednesday, March 11th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.05. Afya had a return on equity of 18.77% and a net margin of 20.31%.The company had revenue of $147.08 million during the quarter, compared to analyst estimates of $174.74 million. On average, equities analysts anticipate that Afya Limited will post 1.52 EPS for the current year.

Afya Dividend Announcement

The firm also recently disclosed an annual dividend, which was paid on Monday, April 6th. Investors of record on Wednesday, March 25th were given a $0.656 dividend. The ex-dividend date was Wednesday, March 25th. This represents a dividend yield of 433.0%. Afya's payout ratio is currently 45.21%.

Hedge Funds Weigh In On Afya

Large investors have recently bought and sold shares of the company. Swedbank AB acquired a new position in Afya during the 3rd quarter worth approximately $1,092,000. SPX Gestao de Recursos Ltda acquired a new position in Afya during the 3rd quarter worth approximately $2,895,000. Doma Perpetual Capital Management LLC boosted its position in Afya by 50.6% during the 3rd quarter. Doma Perpetual Capital Management LLC now owns 891,639 shares of the company's stock worth $13,910,000 after acquiring an additional 299,419 shares during the last quarter. Quantbot Technologies LP acquired a new position in Afya during the 2nd quarter worth approximately $117,000. Finally, Militia Capital Partners LP acquired a new position in Afya during the 2nd quarter worth approximately $71,000. Institutional investors and hedge funds own 88.02% of the company's stock.

Analyst Upgrades and Downgrades

AFYA has been the subject of several research analyst reports. Weiss Ratings reiterated a "hold (c)" rating on shares of Afya in a research report on Wednesday, January 21st. Bank of America lowered Afya from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $22.00 to $17.00 in a research report on Tuesday, February 24th. UBS Group reiterated a "neutral" rating and issued a $16.00 price objective (down from $18.00) on shares of Afya in a research report on Friday, January 16th. Wall Street Zen upgraded Afya from a "buy" rating to a "strong-buy" rating in a research report on Saturday, March 14th. Finally, JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $22.00 price objective (down from $24.50) on shares of Afya in a research report on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $17.30.

Check Out Our Latest Analysis on Afya

About Afya

(Get Free Report)

Afya Ltd. operates as a leading provider of medical education and training services in Brazil. The company offers a comprehensive suite of educational programs that span undergraduate medical degrees, residency exam preparation, continuing medical education (CME) and digital learning platforms. Through a network of partner institutions and its own campus operations, Afya supports students at every stage of the medical training continuum, from enrollment in medical schools to ongoing professional development for practicing physicians.

At the core of Afya's offerings is its undergraduate medical program, delivered through a combination of in-person courses at affiliated campuses and fully digital curricula.